» Articles » PMID: 36562786

Identifying Optimal Candidates for Post-TIPS Patients with HCC Undergoing TACE: a Multicenter Observational Study

Abstract

Objective: To develop a prognostic model for post-transjugular intrahepatic portosystemic shunt (TIPS) patients with hepatocellular carcinoma (HCC) beyond the Milan criteria treated by transarterial chemoembolization (TACE).

Design: Between January 2013 and January 2020, 512 patients with HCC beyond the Milan criteria who underwent TACE after TIPS were retrospectively recruited from 15 tertiary centers. Patients were randomly sorted into a training set (n = 382) and a validation set (n = 130). Medical data and overall survival were assessed. A prediction model was developed using multivariate Cox regression analyses. Predictive performance and discrimination were evaluated and compared with other prognostic models.

Results: Vascular invasion, log(AFP), 1/creatinine, extrahepatic spread, and log(ALT) were the most significant prognostic factors of survival. These five parameters were included in a new VACEA score. This score was able to stratify patients in the training set into four distinct risk grades whose median overall survival were 25.2, 15.1, 8.9, and 6.2 months, respectively. The 6-month, 1-year, 2-year, and 3-year AUROC values and C-index of the VACEA model were 0.819, 0.806, 0.779, 0.825, and 0.735, respectively, and higher than those of other seven currently available models in both the training and validation sets, as well as in different subgroups.

Conclusion: The VACEA score could stratify post-TIPS patients with HCC beyond the Milan criteria treated by TACE and help to identify candidates who benefit from this treatment.

Key Points: • Vascular invasion, AFP, creatinine, extrahepatic spread, and ALT were independent significant prognostic factors of survival for HCC patients who underwent TACE after TIPS. • Our new model, named VACEA score, can accurately predict prognosis at the individual level and stratify patients into four distinct risk grades. • The VACEA model showed better prognostic discrimination and calibration than other current TACE-/TIPS-specific models Graphical abstract.

Citing Articles

Gut Microbiota as Mediator and Moderator Between Hepatitis B Virus and Hepatocellular Carcinoma: A Prospective Study.

Hu B, Yang Y, Yao J, Lin G, He Q, Bo Z Cancer Med. 2024; 13(24):e70454.

PMID: 39702929 PMC: 11659115. DOI: 10.1002/cam4.70454.


MRI-based prediction of the need for wide resection margins in patients with single hepatocellular carcinoma.

Wang Y, Qu Y, Yang C, Wu Y, Wei H, Qin Y Eur Radiol. 2024; .

PMID: 39235653 DOI: 10.1007/s00330-024-11043-5.


Impact of Sarcopenia on Prognosis in Primary Hepatocellular Carcinoma Patients Treated with Transcatheter Arterial Chemoembolization: A Single Center Retrospective Study.

Bai Y, Liu J, Wang Y, Zhou B, Liu X, Dong X J Cancer. 2024; 15(7):1837-1847.

PMID: 38434977 PMC: 10905400. DOI: 10.7150/jca.92976.


Assessing dynamic metabolic heterogeneity in prostate cancer patients via total-body [Ga]Ga-PSMA-11 PET/CT imaging: quantitative analysis of [Ga]Ga-PSMA-11 uptake in pathological lesions and normal organs.

Chen R, Ng Y, Yang X, Zhu Y, Li L, Zhao H Eur J Nucl Med Mol Imaging. 2023; 51(3):896-906.

PMID: 37889299 DOI: 10.1007/s00259-023-06475-y.


The Role of Transjugular Intrahepatic Portosystemic Shunt (TIPS) in Treating Portal Hypertension in Patients with Hepatocellular Carcinoma.

Balducci D, Montori M, De Blasio F, Di Bucchianico A, Argenziano M, Svegliati Baroni G Medicina (Kaunas). 2023; 59(6).

PMID: 37374354 PMC: 10304577. DOI: 10.3390/medicina59061150.

References
1.
Chan H, Hui Y, Leung N, Ching J, Chan F, Sung J . Risk factors for active liver disease in HBeAg-negative chronic hepatitis B virus-infected patients. Am J Gastroenterol. 2001; 95(12):3547-51. DOI: 10.1111/j.1572-0241.2000.03373.x. View

2.
Han G, Berhane S, Toyoda H, Bettinger D, Elshaarawy O, Chan A . Prediction of Survival Among Patients Receiving Transarterial Chemoembolization for Hepatocellular Carcinoma: A Response-Based Approach. Hepatology. 2019; 72(1):198-212. PMC: 7496334. DOI: 10.1002/hep.31022. View

3.
Lencioni R, De Baere T, Soulen M, Rilling W, Geschwind J . Lipiodol transarterial chemoembolization for hepatocellular carcinoma: A systematic review of efficacy and safety data. Hepatology. 2016; 64(1):106-16. DOI: 10.1002/hep.28453. View

4.
Jung K, Kim S, Song K, Park J, Kim D, Ahn S . Validation of hepatitis B virus-related hepatocellular carcinoma prediction models in the era of antiviral therapy. Hepatology. 2015; 62(6):1757-66. DOI: 10.1002/hep.28115. View

5.
Kohi M, Fidelman N, Naeger D, LaBerge J, Gordon R, Kerlan Jr R . Hepatotoxicity after transarterial chemoembolization and transjugular intrahepatic portosystemic shunt: do two rights make a wrong?. J Vasc Interv Radiol. 2012; 24(1):68-73. DOI: 10.1016/j.jvir.2012.08.032. View